Physiogenex will attend the Keystone Unraveling the Secrets of Kidney Disease meeting on March 4th, 2019 during the Poster Session 1 (19:30 – 22:00).
Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our Diabetic Nephropathy models.
Poster (#1002) SGLT2 inhibitor dapagliflozin reduces hyperfiltration and prevents glomerular filtration rate decline in rodent models of diabetic nephropathy”.
Dr. Briand will be happy to discuss with you about your preclinical Diabetic Nephropathy project, explore it and share with you his expertise. Please Contact us to set-up an appointment.
About us
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.